{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T18:12:39Z","timestamp":1792692759289,"version":"4.5.0"},"reference-count":13,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2025,3,24]],"date-time":"2025-03-24T00:00:00Z","timestamp":1742774400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,4,4]]},"abstract":"Abstract<\/jats:title>\n \n Background and Aims<\/jats:title>\n Janus kinase (JAK) inhibitors, such as tofacitinib, are potent anti-inflammatory agents used in the treatment of ulcerative colitis (UC). Current guidelines recommend avoiding their use during pregnancy due to safety concerns, as well as during breastfeeding due to the potential excretion into breast milk.<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n This case report describes the impact of in utero exposure to tofacitinib during pregnancy and subsequent exposure via breastfeeding on the immune development of the exposed infant.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n A 37-year-old woman with UC, who was being treated with tofacitinib and vedolizumab, became pregnant and continued both medications, with the tofacitinib dosage reduced from 10 to 5\u00a0mg BID at gestational week 28. The infant was born healthy, with normal growth and development, and received all scheduled non-live vaccinations. At 15 months, immune parameters\u2014including response to vaccination\u2014were evaluated. The results showed normal immunoglobulin levels and an adequate serologic response to vaccination, with no signs of immune dysfunction.<\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n This case suggests that prolonged prenatal and postnatal exposure to tofacitinib may not adversely affect infant immune development. However, caution is advised due to the limited number of documented cases. Further research is needed to fully understand the long-term implications of JAK inhibitor exposure during pregnancy and breastfeeding.<\/jats:p>\n <\/jats:sec>","DOI":"10.1093\/ecco-jcc\/jjaf049","type":"journal-article","created":{"date-parts":[[2025,3,28]],"date-time":"2025-03-28T03:55:47Z","timestamp":1743134147000},"source":"Crossref","is-referenced-by-count":7,"title":["Effect of tofacitinib exposure in utero and during breastfeeding<\/i> on the immune status of exposed child"],"prefix":"10.1093","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1836-3745","authenticated-orcid":false,"given":"Katarina","family":"Mitrova","sequence":"first","affiliation":[{"name":"Department of Paediatrics, 2nd Faculty of Medicine, Charles University in Prague and Motol University Hospital , Prague,","place":["Czech Republic"]},{"name":"IBD Clinical and Research Centre, ISCARE a.s. , Prague,","place":["Czech Republic"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Kostrejova","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Hospital of the Sisters of Mercy of St. Charles Borromeo , Prague,","place":["Czech Republic"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristyna","family":"Zdychyncova","sequence":"additional","affiliation":[{"name":"IBD Clinical and Research Centre, ISCARE a.s. , Prague,","place":["Czech Republic"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1463-3840","authenticated-orcid":false,"given":"Milan","family":"Lukas","sequence":"additional","affiliation":[{"name":"IBD Clinical and Research Centre, ISCARE a.s. , Prague,","place":["Czech Republic"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dana","family":"Duricova","sequence":"additional","affiliation":[{"name":"IBD Clinical and Research Centre, ISCARE a.s. , Prague,","place":["Czech Republic"]},{"name":"Department of Pharmacology, 1st Faculty of Medicine, Charles University in Prague , Prague,","place":["Czech Republic"]},{"name":"Hepatogastroenterology Clinic, Institute of Clinical and Experimental Medicine , Prague,","place":["Czech Republic"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,3,24]]},"reference":[{"key":"2025042106114627900_CIT0001","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/ecco-jcc\/jjac115","article-title":"European Crohn\u2019s and Colitis Guidelines on sexuality, fertility, pregnancy, and lactation","volume":"17","author":"Torres","year":"2023","journal-title":"J Crohns Colitis."},{"key":"2025042106114627900_CIT0002","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.cgh.2024.01.019","article-title":"Tofacitinib in pregnancy: assessing pregnancy and infant outcomes, cord blood, and breast milk concentrations","volume":"23","author":"Mitrova","year":"2025","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2025042106114627900_CIT0003","doi-asserted-by":"publisher","first-page":"e8764","DOI":"10.1002\/ccr3.8764","article-title":"First-trimester exposure to tofacitinib in ulcerative colitis: a case report of a healthy newborn and literature review","volume":"12","author":"Arzivian","year":"2024","journal-title":"Clin Case Rep"},{"key":"2025042106114627900_CIT0004","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1093\/ibd\/izae076","article-title":"Tofacitinib as a rescue therapy for ulcerative colitis in pregnancy","volume":"30","author":"Rowan","year":"2024","journal-title":"Inflamm Bowel Dis."},{"key":"2025042106114627900_CIT0005","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1007\/s40264-024-01454-0","article-title":"Pregnancy outcomes in patients treated with upadacitinib: analysis of data from clinical trials and postmarketing reports","volume":"47","author":"Mahadevan","year":"2024","journal-title":"Drug Saf."},{"key":"2025042106114627900_CIT0006","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1007\/s40261-024-01353-3","article-title":"Experience of tofacitinib use in pregnancy in patients with ulcerative colitis","volume":"44","author":"Chaparro","year":"2024","journal-title":"Clin Drug Investig."},{"key":"2025042106114627900_CIT0007","doi-asserted-by":"publisher","first-page":"34","DOI":"10.3390\/jcm13010034","article-title":"Reproductive safety issues of novel small molecules for the treatment of inflammatory bowel disease: a systematic review","volume":"13","author":"Monfared","year":"2023","journal-title":"J Clin Med"},{"key":"2025042106114627900_CIT0008","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1007\/s40265-020-01346-4","article-title":"Safety of new biologics (vedolizumab and ustekinumab) and small molecules (tofacitinib) during pregnancy: a review","volume":"80","author":"Gisbert","year":"2020","journal-title":"Drugs."},{"key":"2025042106114627900_CIT0009","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1016\/S2468-1253(23)00158-9","article-title":"Tofacitinib concentrations in plasma and breastmilk of a lactating woman with ulcerative colitis","volume":"8","author":"Julsgaard","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2025042106114627900_CIT0010","doi-asserted-by":"publisher","first-page":"100149","DOI":"10.1016\/j.crtox.2024.100149","article-title":"Placental transfer of tofacitinib in the ex vivo dual-side human placenta perfusion model","volume":"6","author":"Eliesen","year":"2024","journal-title":"Curr Res Toxicol"},{"key":"2025042106114627900_CIT0011","doi-asserted-by":"publisher","first-page":"otae006","DOI":"10.1093\/crocol\/otae006","article-title":"Normal infant immunologic assessment and uneventful live rotavirus vaccination despite continuous tofacitinib exposure in utero and during breastfeeding","volume":"6","author":"Ernest-Suarez","year":"2024","journal-title":"Crohns Colitis 360."},{"key":"2025042106114627900_CIT0012","volume-title":"Drugs and Human Lactation: A Comprehensive Guide to the Content and Consequences of Drugs, Micronutrients, Radiopharmaceuticals, and Environmental and Occupational Chemicals in Human Milk","author":"Bennett","year":"1996","edition":"2nd ed"},{"key":"2025042106114627900_CIT0013","doi-asserted-by":"publisher","first-page":"S59","DOI":"10.1016\/j.jped.2020.10.006","article-title":"Immune system: development and acquisition of immunological competence","volume":"97 Suppl 1","author":"de Moraes-Pinto","year":"2021","journal-title":"J Pediatr (Rio J)"}],"container-title":["Journal of Crohn's and Colitis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/advance-article-pdf\/doi\/10.1093\/ecco-jcc\/jjaf049\/62574333\/jjaf049.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article-pdf\/19\/4\/jjaf049\/62574333\/jjaf049.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article-pdf\/19\/4\/jjaf049\/62574333\/jjaf049.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,21]],"date-time":"2025-04-21T10:12:02Z","timestamp":1745230322000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article\/doi\/10.1093\/ecco-jcc\/jjaf049\/8092496"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,24]]},"references-count":13,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4,4]]}},"URL":"https:\/\/doi.org\/10.1093\/ecco-jcc\/jjaf049","relation":{},"ISSN":["1873-9946","1876-4479"],"issn-type":[{"value":"1873-9946","type":"print"},{"value":"1876-4479","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,4]]},"published":{"date-parts":[[2025,3,24]]},"article-number":"jjaf049"}}